



# Fruzaqla (fruquintinib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION	
LAST NAME:	FIRST NAME:
PHONE NUMBER:	DATE OF BIRTH:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
PATIENT INSURANCE ID NUMBER:	

MALE  FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_\_ ALLERGIES: \_\_\_\_\_

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI DISCLOSURE AUTHORIZATION.PDF](https://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): \_\_\_\_\_  
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: \_\_\_\_\_

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page





# Fruzaqla (fruquintinib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

<b>1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?</b> <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
<b>MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):</b>  	<b>DURATION OF THERAPY (SPECIFY DATES):</b>  	<b>RESPONSE/REASON FOR FAILURE/ALLERGY:</b>  
<b>2. LIST DIAGNOSES:</b>		<b>ICD-10:</b>
<input type="checkbox"/> Metastatic colorectal cancer(mCRC) <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____		
<b>3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.</b>		
<p>Is patient going to be using drug in a clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Did patient progress on or was intolerant to treatment with either Lonsurf(trifluridine/tipiracil) or Stivarga(regorafenib) or both? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p>Has patient been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p>Has patient been previously treated with an anti-VEGF therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p>Is patient's tumor RAS wild-type? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p>If patient's tumor is RAS wild-type, and medically appropriate, was patient treated with an anti-EGFR therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p>Does patient have microsatellite-high (MSI-H) or mismatch repair deficient (dMMR) tumors? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p>If patient has microsatellite-high (MSI-H) or mismatch repair deficient (dMMR) tumors, was patient treated with immune checkpoint inhibitors? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p>Was patient ineligible for treatment with a checkpoint inhibitor? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p>Does patient have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1?</p> <p>Does patient have BRAF-mutant tumors? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p>If patient has a BRAF-mutant tumor, was patient treated with a BRAF inhibitor? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p>Was the patient ineligible for treatment with a BRAF inhibitor? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p>		





**Fruzaqla (fruquintinib)  
Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

**MEMBER'S LAST NAME:** \_\_\_\_\_ **MEMBER'S FIRST NAME:** \_\_\_\_\_

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

\_\_\_\_\_

\_\_\_\_\_

**Please note:** Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

**ATTESTATION:** I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature or Electronic I.D. Verification:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

**FAX THIS FORM TO: 800-424-7640**

**MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program Attn:CP-4201**

P.O.Box 64811

St. Paul, MN 55164-0811

Phone: 877-228-7909

